The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ONCY | -3.28% | -47.79% | -12.18% | -98% |
| S&P | +14.5% | +93.32% | +14.09% | +525% |
Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.
The cards are certainly stacked against this biotech stock. But if its experimental lead drug proves effective, the sky could be the limit.
Oncolytics announces successful tests for cancer drug Reolysin.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.07M | 5.2% |
| Market Cap | $68.66M | -8.6% |
| Market Cap / Employee | $2.45M | 0.0% |
| Employees | 28 | 3.7% |
| Net Income | -$4.45M | 16.0% |
| EBITDA | -$4.06M | 29.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.75M | -52.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.44M | -32.8% |
| Short Term Debt | $0.21M | 29.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -114.75% | -27.7% |
| Return On Invested Capital | -168.91% | 10961.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.12M | 17.9% |
| Operating Free Cash Flow | -$4.12M | 16.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.00 | 10.51 | 10.58 | 14.81 | 236.57% |
| Price to Tangible Book Value | 5.00 | 10.51 | 10.58 | 14.81 | 236.57% |
| Enterprise Value to EBITDA | -7.43 | -10.18 | -7.61 | -14.86 | 46.54% |
| Return on Equity | -144.2% | -184.7% | -211.2% | -244.8% | 78.41% |
| Total Debt | $0.79M | $0.74M | $0.69M | $0.65M | -20.21% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
